<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24411/2587-7836-2018-10016.</article-id><article-id custom-type="elpub" pub-id-type="custom">phkinetica-62</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ТОКСИКОЛОГИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TOXICOLOGY STUDY</subject></subj-group></article-categories><title-group><article-title>Исследование острой токсичности ГМЛ-1</article-title><trans-title-group xml:lang="en"><trans-title>Study of acute toxicity of the drug GML-1</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мирошкина</surname><given-names>Ирина Александровна</given-names></name><name name-style="western" xml:lang="en"><surname>Sorokina</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сорокина</surname><given-names>Александра Валериановна</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseeva</surname><given-names>S. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>Светлана Витальевна</given-names></name><name name-style="western" xml:lang="en"><surname>Miroshkina</surname><given-names>I. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волкова</surname><given-names>Анна Валерьевна</given-names></name><name name-style="western" xml:lang="en"><surname>Volkova</surname><given-names>A. V.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дурнев</surname><given-names>Андрей Дмитриевич</given-names></name><name name-style="western" xml:lang="en"><surname>Durnev</surname><given-names>A. D.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «НИИ фармакологии имени В.В. Закусова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBI «Zakusov Institute of Pharmacology»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>06</day><month>03</month><year>2018</year></pub-date><volume>0</volume><issue>2</issue><fpage>65</fpage><lpage>70</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мирошкина И.А., Сорокина А.В., Алексеева С.В., Волкова А.В., Дурнев А.Д., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Мирошкина И.А., Сорокина А.В., Алексеева С.В., Волкова А.В., Дурнев А.Д.</copyright-holder><copyright-holder xml:lang="en">Sorokina A.V., Alekseeva S.V., Miroshkina I.A., Volkova A.V., Durnev A.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/62">https://www.pharmacokinetica.ru/jour/article/view/62</self-uri><abstract/><trans-abstract xml:lang="en"><p>Resume. Relevance. The acute toxicity evaluation is the anecessary stage of preclinical research of the new original anxiolytic drug GML-1. The present investigation aim is study of the GML-1 acute toxicity. Methods. GML-1 was administered once orally and intraperitoneally to mice and rats in the maximum possible volumes for each of the administration methods and for each animal species, at the highest possible concentrations. Equivalent volume of 1 % starch solution was administered to animals of the control groups. Euthanasia and pathoanatomical dissection were performed 14 days after the drug administration. The animal intoxication periods with a detailed description of the observed clinical picture were registered. Results. The mean lethal doses were not identified because GML-1 did not cause death of animals at injection of the maximum allowable volumes and maximum allowable concentrations. The morphological view of the internal organs, detected during pathoanatomical dissection of all experimental animals, did not differ from that observed in control animals. Conclusion. It was determined that the drug GML-1 at oral and intraperitoneal injection concerns to low-toxic substances. According to classification Sidorov K.K. (1973) this drug may be related to 4th toxicity class.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ГМЛ-1</kwd><kwd>острая токсичность</kwd><kwd>мыши</kwd><kwd>крысы</kwd><kwd>GML-1</kwd><kwd>acute toxicity</kwd><kwd>mice</kwd><kwd>rats</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Красовский Г.Н., Рахманин Ю.А., Егорова Н.А. Экстраполяция токсикологических данных с животных на человека. -М.: Медицина; 2009.</mixed-citation><mixed-citation xml:lang="en">Красовский Г.Н., Рахманин Ю.А., Егорова Н.А. Экстраполяция токсикологических данных с животных на человека. -М.: Медицина; 2009.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Беленький М.Б. Элементы количественной оценки фармакологического эффекта. - Л.: Медгиз; 1963.</mixed-citation><mixed-citation xml:lang="en">Беленький М.Б. Элементы количественной оценки фармакологического эффекта. - Л.: Медгиз; 1963.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по проведению доклинических исследований лекарственных средств. Ч. 1. Методические рекомендации по изучению общетоксического действия лекарственных средств. Изучение острой токсичности. - М.: Гриф и К; 2012. - С. 15-17.</mixed-citation><mixed-citation xml:lang="en">Руководство по проведению доклинических исследований лекарственных средств. Ч. 1. Методические рекомендации по изучению общетоксического действия лекарственных средств. Изучение острой токсичности. - М.: Гриф и К; 2012. - С. 15-17.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Guide for the Care and Use of Laboratory Animals. National Academies Press (US). Washington (DC). 2011. DOI: 10.17226/12910</mixed-citation><mixed-citation xml:lang="en">Guide for the Care and Use of Laboratory Animals. National Academies Press (US). Washington (DC). 2011. DOI: 10.17226/12910</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Правила доклинической оценки безопасности фармакологических средств. РД 64-126-91. - М.: МЗ России, ФК; 1992.</mixed-citation><mixed-citation xml:lang="en">Правила доклинической оценки безопасности фармакологических средств. РД 64-126-91. - М.: МЗ России, ФК; 1992.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Методические указания по изучению общетоксического действия фармакологических веществ. - М.: Медицина; 2005. С.41-47.</mixed-citation><mixed-citation xml:lang="en">Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Методические указания по изучению общетоксического действия фармакологических веществ. - М.: Медицина; 2005. С.41-47.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Гацура В.В. Методы первичного фармакологического исследования биологически активных веществ. - М.: Медицина; 1974.</mixed-citation><mixed-citation xml:lang="en">Гацура В.В. Методы первичного фармакологического исследования биологически активных веществ. - М.: Медицина; 1974.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
